INSM
Insmed Incorporated · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +6.4% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 1.33M | $149.97M | n/a | −2 |
| Q2 2026 | 156 | -6 | 147.06M | $15.68B | +6 | −13 |
| Q1 2026 | 166 | +6 | 152.11M | $24.63B | +9 | −4 |
| Q4 2025 | 159 | -1 | 156.45M | $27.23B | +1 | −1 |
| Q3 2025 | 21 | +1 | 121.03M | $17.43B | +1 | −1 |
| Q2 2025 | 18 | +1 | 70.35M | $7.08B | +2 | −1 |
| Q1 2025 | 14 | -1 | 33.99M | $2.59B | n/a | −1 |
| Q4 2024 | 15 | 0 | 31.46M | $2.17B | +1 | −1 |
| Q3 2024 | 14 | -1 | 23.46M | $1.71B | n/a | −1 |
| Q2 2024 | 15 | n/a | 25.91M | $1.74B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 12.70M | +1.0% | $877.11M | 0.1% | ▲ Add | 3 | SEC ↗ ×2 |
| 2 | State Street Global Advisors ✦ (passive) | 6.11M | n/a | $421.57M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (passive) | 4.09M | +7.2% | $282.24M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 4 | Norges Bank ✦ (passive) | 1.83M | +10.7% | $126.61M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 5 | Adage Capital Partners ✦ | 1.65M | +59.6% | $113.75M | 0.2% | ▲ Add | 3 | SEC ↗ |
| 6 | Marshall Wace ✦ | 1.06M | +38.0% | $73.47M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 7 | Wellington Management ✦ | 752.23K | -21.8% | $51.93M | 0.0% | ▼ Trim | 3 | SEC ↗ ×6 |
| 8 | Millennium Management ✦ | 699.01K | +23.8% | $48.26M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 9 | Two Sigma Investments ✦ | 594.00K | -25.9% | $41.01M | 0.1% | ▼ Trim | 3 | SEC ↗ |
| 10 | Duquesne Family Office ✦ | 593.47K | +2867.3% | $40.97M | 1.2% | ▲ Add | 3 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 508.79K | +662.4% | $35.13M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 12 | Soros Fund Management ✦ | 455.09K | -4.9% | $31.42M | 0.8% | ▼ Trim | 3 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 323.74K | -3.8% | $22.35M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 14 | AQR Capital Management ✦ | 64.17K | +2.0% | $4.43M | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 15 | Renaissance Technologies ✦ | 25.29K | New | $1.75M | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Renaissance Technologies | $1.75M | 0.0% |
Exited
| Point72 Asset Management | $23.01M | was 0.1% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 664 holders, 192.22M shares, $30.07B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 25.00K sh · $3.10M
Director · 5.00K sh · $637,650
Officer · 239.85K sh · $31.96M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology